Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 6/20 | 0.34 |
| ▸ | GABRA5 | P31644 | 6/20 | 0.34 |
| ▸ | GABRG2 | P18507 | 5/20 | 0.34 |
| ▸ | GABRB3 | P28472 | 5/20 | 0.34 |
| ▸ | GABRA3 | P34903 | 5/20 | 0.34 |
| ▸ | GABRA2 | P47869 | 5/20 | 0.34 |
| ▸ | GABRA4 | P48169 | 3/20 | 0.34 |
| ▸ | GABRA6 | Q16445 | 3/20 | 0.34 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18097560 | 0.80 | FFAR1 (0.34) | GABRA1GABRA5GABRG2GABRB3GABRA3 | |
| SCHEMBL2724438 | 0.77 | CYP2A6 (0.38) | — | |
| SCHEMBL3344789 | 0.76 | FFAR1 (0.35) | GABRA1GABRA5GABRG2GABRB3GABRA3 | |
| SCHEMBL5736767 | 0.76 | GABRA1 (0.35) | GABRA1GABRA5GABRG2GABRB3GABRA3 | |
| SCHEMBL7551034 | 0.74 | GABRA1 (0.36) | GABRA1GABRA5GABRG2GABRB3GABRA3 | |
| SCHEMBL7716869 | 0.71 | GABRA1 (0.34) | GABRA1GABRA5GABRG2GABRB3GABRA3 | |
| SCHEMBL2561411 | 0.70 | SRC (0.42) | — | |
| SCHEMBL31176234 | 0.70 | SRC (0.42) | — | |
| SCHEMBL6757126 | 0.70 | HTR5A (0.32) | — | |
| SCHEMBL24132876 | 0.69 | LOX (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2003095441-A1 | INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME | PFIZER INC. (US) | 2003-11-20 | — | — | WO | disclosed |